Western countries consider stockpiles, place orders for vaccine against monkeypox
The US, Canada, UK, France, Germany, and Spain are among several countries to purchase vaccine doses.
Several countries in Europe and North America have started offering vaccines for monkeypox to their most exposed citizens, as cases of the viral disease continue to rise.
There is currently no specific vaccine for monkeypox, but data shows that vaccines used to eradicate smallpox are up to 85% effective against it, according to the World Health Organisation. The vaccine is made by Danish biotech Bavarian Nordic and goes under the name Imvanex in the European Union, Imvamune in Canada, and Jynneos in the US.
Last week, the EU agreed on common purchasing of the vaccine and the UK struck a deal for 20,000 doses. Canada said it had started pre-positioning the Imvamune vaccine from its national emergency stockpile across the country, while the US said it was in the process of releasing the Jynneos vaccine. US officials said there were more than 1,000 doses of the vaccine in the national stockpile and they expected that level to ramp up quickly in the coming weeks.
Several countries are also striking deals to purchase the antiviral tecovirimat, developed by US-based SIGA Technologies. Tecovirimat, sold under the brand name TPOXX among others, is an oral medication which is approved in Europe as a treatment against orthopoxviruses such as smallpox and monkeypox.
Global health officials have tracked more than 300 suspected and confirmed cases of the viral infection in about 20 countries since early May. Monkeypox is a usually mild viral infection that is endemic in parts of west and central Africa.
Symptoms of the disease - which can include fever, distinctive rashes and pus-filled skin lesions - can last for two to four weeks, but often resolve on their own. The variant of the virus implicated in the current outbreak is believed to kill a small fraction of those infected.
Last week, a senior World Health Organisation official advised that countries take steps to contain the spread of the disease and share data about their vaccine stockpiles.
‘We think that if we put in place the right measures now, we probably can contain this easily,’ Sylvie Briand, WHO director for Global Infectious Hazard Preparedness, told the UN agency's annual assembly.
She said: ‘We don't know exactly the number of doses available in the world and so that’s why we encourage countries to come to WHO and tell us what are their stockpiles.’
While the size of global supply is unclear, it is estimated to be quite constrained. WHO officials are advising against mass vaccination, instead suggesting targeted administration where available for close contacts of people infected.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance